UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): August 30, 2019

 

CO-DIAGNOSTICS, INC.

(Exact name of small business issuer as specified in its charter)

 

Utah   1-38148   46-2609363
(State or other jurisdiction
of incorporation or organization) 		 

(Commission

File Number)

 

(IRS Employer

Identification Number)

 

2401 S. Foothill Drive, Suite D, Salt Lake City, Utah 84109

(Address of principal executive offices)

 

(801) 438-1036

(Issuer’s telephone number)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Stock, par value $0.001 per share   CODX   NASDAQ Capital Market

 

Emerging growth company [X]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

 

 

 
 

 

Item 5.07. Submission of Matters to a Vote of Security Holders

 

Co-Diagnostics, Inc. (the “Company”) held its Annual Meeting on August 30, 2019 at its principal executive offices. According to the inspector of elections, the stockholders present in person or by proxy represented 11,677,730 shares of common stock (entitled to one vote per share) which was equal to 68.2% of the shares of common stock entitled to vote. At the Annual Meeting, the stockholders voted on the following two proposals and cast their votes as follows:

 

Proposal 1: Election of Directors.

 

Director   Votes For     Votes Withheld     Broker Non-Votes  
Dwight H. Egan     7,576,981       35,383       3,743,684  
Eugene Durenard     7,577,281       35,083       3,743,684  
Edward L. Murphy     7,577,534       34,830       3,743,684  
Richard S. Serbin     7,578,281       34,083       3,743,684  
James Nelson     7,071,160       541,204       3,743,684  

 

Each of the individuals listed above was elected as a director of the Company to serve until the 2020 annual meeting of stockholders and until successors are duly elected or until the earliest of their removal or resignation.

 

Proposal 2: Ratification of the appointment of Haynie & Company as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.

 

Votes For   Votes Against     Votes Abstain  
11,402,369     129,312       146,049  

 

The stockholders voted to ratify the selection of Haynie & Company as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.

 

 
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

  CO-DIAGNOSTICS, INC.
     
  By: /s/ Dwight H. Egan
  Name: Dwight H. Egan
  Title: Chief Executive Officer

 

Date: September 5, 2019

 

 
 

 

Co Diagnostics (NASDAQ:CODX)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024 Haga Click aquí para más Gráficas Co Diagnostics.
Co Diagnostics (NASDAQ:CODX)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024 Haga Click aquí para más Gráficas Co Diagnostics.